Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Critical Limb Ischemia (CLI) Clear all
Completed Phase 3 Interventional

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00059657
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Ecraprost in lipid emulsion
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
40 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 19, 2006 · Synced Sep 30, 2026, 5:41 PM EDT
Completed No phase listed Observational

Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study

NCT04304105
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Artery Disease
Interventions
Not listed
Lead sponsor
LimFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Timeline
2020 – 2022
U.S. locations
24
States / cities
Los Angeles, California • Torrance, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia

NCT01867190
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
ASCT01 (Autologous Stem Cell Transplantation)
Biological
Lead sponsor
Lifecells, LLC.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Sep 30, 2026, 5:41 PM EDT
Recruiting Not applicable Interventional

Ultrasound Cavitation Therapy for CLI

NCT05749250
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Acoustic cavitation of ultrasound enhancing agents
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Not applicable Interventional

BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI

NCT02601430
View directory record Official record
Conditions
Peripheral Arterial Disease, Critical Limb Ischemia
Interventions
BOLD-MRI
Other
Lead sponsor
Zimmer Biomet
Industry
Eligibility
19 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00059644
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Ecraprost in lipid emulsion
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
40 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Sep 30, 2026, 5:41 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03886506
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
PLX-PAD
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
45 Years to 99 Years
U.S. locations
2
States / cities
Clifton, New Jersey • Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

NCT00060996
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Interventions
Remodulin® (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

NCT00951210
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
PLX-PAD
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
40 Years to 81 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Birmingham, Alabama • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 30, 2026, 5:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

NCT02805023
View directory record Official record
Conditions
Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
BGC101 (autologous EnEPC preparation), Control medium
Biological
Lead sponsor
BioGenCell Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
San Francisco, California • New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)

NCT01049919
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
Bone marrow concentration device, Placebo procedure (sham)
Device · Procedure
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
25
States / cities
Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Sep 30, 2026, 5:41 PM EDT
Not listed No phase listed Observational

The Use of FlowMet-R Technology to Predict Wound Healing in CLI Patients in a Wound Care Center Setting

NCT05455554
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Flowmet-D, ABI
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
30 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Sep 30, 2026, 5:41 PM EDT
Recruiting Not applicable Interventional

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

NCT05313165
View directory record Official record
Conditions
Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease
Interventions
LimFlow Stent Graft System
Device
Lead sponsor
LimFlow, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
30
States / cities
La Jolla, California • Palo Alto, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional

ALD-301 for Critical Limb Ischemia, Randomized Trial

NCT00392509
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
ALDH-br bone marrow cells vs. mononuclear bone marrow cells
Procedure
Lead sponsor
Aldagen
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2009 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Not applicable Interventional

Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)

NCT00498069
View directory record Official record
Conditions
Ischemia
Interventions
Harvest Smartprep2 BMAC System, SmartPReP2 BMAC System, placebo
Device · Biological
Lead sponsor
Harvest Technologies
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
6
States / cities
Tampa, Florida • Boston, Massachusetts • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 3 Interventional

An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

NCT01483898
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Ixmyelocel-T, Placebo
Biological · Other
Lead sponsor
Vericel Corporation
Industry
Eligibility
35 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 30, 2026, 5:41 PM EDT
Not listed Not applicable Interventional Results available

PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

NCT03970538
View directory record Official record
Conditions
Critical Limb Ischemia, Critical Lower Limb Ischemia, Peripheral Artery Disease, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, Arterial Occlusive Diseases, Arterial Occlusion, Arterial Disease, Peripheral Artery Occlusion, Peripheral Vascular Disease, Peripheral Ischemia, Vascular Diseases
Interventions
LimFlow System
Device
Lead sponsor
LimFlow, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
San Francisco, California • Torrance, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

NCT02016755
View directory record Official record
Conditions
Critical Limb Ischemia, Vascular Diseases, Peripheral Arterial Disease
Interventions
HGF Plasmid
Biological
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Sep 30, 2026, 5:41 PM EDT
Recruiting Not applicable Interventional

FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW

NCT06492733
View directory record Official record
Conditions
Chronic Total Occlusion of Artery of the Extremities
Interventions
FastWire System - Peripheral
Device
Lead sponsor
Versono Medical Ltd
Industry
Eligibility
18 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Wilmington, Delaware • Cocoa, Florida • Davenport, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 30, 2026, 5:41 PM EDT
Completed No phase listed Observational

SCOPE CLI (Shifting Care and Outcomes for Patients With Endangered Limbs - Critical Limb Ischemia)

NCT03171259
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
care as usual
Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Sep 30, 2026, 5:41 PM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

NCT00067041
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Remodulin (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
4
States / cities
Springfield, Illinois • Worcester, Massachusetts • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 30, 2026, 5:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)

NCT02094755
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Blood draw only
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Sep 30, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

NCT01386216
View directory record Official record
Conditions
Critical Limb Ischemia (CLI), Peripheral Vascular Disease (PVD)
Interventions
Magellan®
Device
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 30, 2026, 5:41 PM EDT
Active, not recruiting No phase listed Observational

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs

NCT04710563
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 30, 2026, 5:41 PM EDT